Medtide launches IPO to bulk up its weight-loss business
The pharmaceutical services firm wants to expand production of peptides used in anti-obesity drugs, but it faces fierce competition and other business risks Key Takeaways: The global market for developing…
So-Young rethinks reverse share split as its stock surges
The cosmetic surgery specialist’s shares have nearly doubled in the last two weeks as investors flock to its new business model centered on self-operated clinics Key Takeaways: So-Young has delayed…
Alphamab stake sale could signal harder times ahead
The founder of the cancer drug developer has cashed out part of his holdings after the stock hit a price peak, raising questions about the firm’s earnings outlook Key Takeaways:…
CSPC Pharma teases big bucks deals after earnings miss
The Chinese drug giant revealed it was in talks with three parties to license its products for up to $5 billion in potential fees, a day after it delivered lackluster…
Its revenue falling, Dazhong Dental looks to M&A to brighten its outlook
The company has filed to list in Hong Kong, aiming to jumpstart its falling revenue and profits by buying up rivals in China’s fragmented dental services market Key Takeaways: Dazhong…
Sinotau aims to become Hong Kong’s ‘first nuclear-medicine stock’
The company is China’s first to obtain approval for its innovative radiopharmaceuticals Key Takeaways: Sinotau has filed to list in Hong Kong, offering up two commercialized products and a net…
3SBio hits the big time with $6 billion cancer drug deal
The pharma giant Pfizer has bought international rights to the experimental cancer therapy and will take a $100 million equity stake in the Chinese drug developer Key Takeaways: The mega…
Recent Articles
RELATED ARTICLES
-
CARsgen seeks cell therapy breakthrough but stays in the red for now
2171.HK -
Everest Medicines drives growth with AI-powered mRNA pipeline
1952.HK
- Cancer drug maker Genfleet joins Hong Kong IPO influx
-
A blockbuster cancer drug? TYK’s claims go under the microscope
2410.HK
-
BeiGene heads for profit milestone after hemorrhaging cash
6160.HK ONC.US 688235.SHG
